Lift Biosciences

Lift Biosciences

Developing the world’s first “off-the-shelf” neutrophil based cancer cell therapy

2020
First invested

LIfT Biosciences was founded by Alex Blyth in 2020 to develop the world’s first “off-the-shelf” neutrophil based cancer cell therapy. The business takes advantage of the natural cancer killing ability that some humans display through their immune systems. Its first mission is to show remission in high unmet need solid tumours by 2024, with an initial focus on pancreatic cancer.

Meet the team